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Abstract
Background: Recombinant monoclonal antibodies have emerged as important tools for cancer therapy. Despite the
promise shown by antibody-based therapies, the large molecular size of antibodies limits their ability to efficiently
penetrate solid tumors and precludes efficient crossing of the blood-brain-barrier into the central nervous system (CNS).
Consequently, poorly vascularized solid tumors and CNS metastases cannot be effectively treated by intravenously-injected
antibodies. The inherent tumor-tropic properties of human neural stem cells (NSCs) can potentially be harnessed to
overcome these obstacles and significantly improve cancer immunotherapy. Intravenously-delivered NSCs preferentially
migrate to primary and metastatic tumor sites within and outside the CNS. Therefore, we hypothesized that NSCs could
serve as an ideal cellular delivery platform for targeting antibodies to malignant tumors.
Methods and Findings: As proof-of-concept, we selected Herceptin
TM (trastuzumab), a monoclonal antibody widely used to
treat HER2-overexpressing breast cancer. HER2 overexpression in breast cancer is highly correlated with CNS metastases,
which are inaccessible to trastuzumab therapy. Therefore, NSC-mediated delivery of trastuzumab may improve its
therapeutic efficacy. Here we report, for the first time, that human NSCs can be genetically modified to secrete anti-HER2
immunoglobulin molecules. These NSC-secreted antibodies assemble properly, possess tumor cell-binding affinity and
specificity, and can effectively inhibit the proliferation of HER2-overexpressing breast cancer cells in vitro. We also
demonstrate that immunoglobulin-secreting NSCs exhibit preferential tropism to tumor cells in vivo, and can deliver
antibodies to human breast cancer xenografts in mice.
Conclusions: Taken together, these results suggest that NSCs modified to secrete HER2-targeting antibodies constitute a
promising novel platform for targeted cancer immunotherapy. Specifically, this NSC-mediated antibody delivery system has
the potential to significantly improve clinical outcome for patients with HER2-overexpressing breast cancer.
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Introduction
Recombinant monoclonal antibodies offer a targeted approach
to cancer therapy and have substantially lower toxicity to normal
cells than chemotherapy. However, their large molecular size and
high affinity to antigens at the tumor border limit the ability of
antibodies to deeply penetrate tumor foci [1]. Central nervous
system (CNS) tumors pose a particular challenge for antibody
therapeutics, because the blood-brain barrier (BBB) prevents
intravenously-injected antibodies from reaching CNS metastases.
The unique tumor-tropic properties of neural stem cells (NSCs)
may provide the means to significantly improve antibody
distribution within metastatic tumor sites throughout the body
[2,3,4,5,6]. NSCs localize to infiltrative tumor cells and hypoxic
tumor regions, which are inaccessible to intravenously adminis-
tered drugs [7]. NSCs are also able to cross the BBB, making them
a potential platform for therapeutic antibody delivery to the brain.
Previous studies have demonstrated that HB1.F3 cells, a clonal,
well-characterized human NSC line [8], can effectively express
and deliver a variety of therapeutic agents to primary and
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[2,4,5,6,9]. Therefore, we hypothesized that NSCs could be used
to enhance antibody-based therapies by delivering antibodies to
previously inaccessible tumor foci, while minimizing the exposure
of normal tissue to the therapeutic agent.
As a model system, we chose Herceptin
TM (trastuzumab), a well
characterized antibody therapy for HER2-overexpressing breast
carcinoma, because HER2-overexpression is correlated with a
poor prognosis and an increased incidence of CNS metastases
[10]. Trastuzumab is a humanized monoclonal antibody that
targets the HER2 receptor, which is overexpressed in approxi-
mately 20–30% of human breast carcinomas [11]. Although the
clinical use of trastuzumab has made measurable improvements in
the prognosis of patients with HER2-overexpressing breast cancer,
its effectiveness is limited [12,13]. In addition, HER2 is expressed
in many normal tissues, giving systemic HER2-targeted antibody
therapy the potential to cause toxicity in a subset of patients,
including cardiac myopathy, congestive heart failure, and
pulmonary toxicity [14,15].
Here we report that HB1.F3 NSCs can be engineered to express
and secrete functional full-length HER2-specific human immuno-
globulin molecules that can selectively bind to and inhibit the
proliferation of HER2-positive breast carcinoma cells. Further-
more, these antibody-secreting NSCs retain tropism to tumor cells
in vitro and can deliver anti-HER2 antibody to tumor foci in vivo.
Our data suggest that NSCs may represent a novel platform for
delivery of therapeutic antibodies to metastatic breast carcinoma.
Results
NSCs Can Express and Secrete Anti-HER2 Antibody
To determine whether NSCs can express immunoglobulins,
HB1.F3 NSCs were transiently co-transfected with plasmids
encoding the heavy and light chains of an anti-HER2 antibody
(HB1.F3.H2IgG) identical in sequence to trastuzumab. Intracel-
lular expression of human immunoglobulin in HB1.F3.H2IgG
NSCs was visualized using immunocytochemistry. In contrast to
parental HB1.F3 NSCs (Fig. 1A), HB1.F3.H2IgG NSCs displayed
a clear intracellular signal when stained with FITC-conjugated
anti-human IgG (Fig. 1B). This signal was often punctate and
localized to the cytoplasm, which is consistent with expected
cellular localization within the endoplasmic reticulum and
secretory vesicles. We next explored viral expression of anti-
HER2 antibody in NSCs in order to prolong antibody expression.
Trastuzumab heavy and light chains were reformatted into a
bicistronic expression cassette and cloned into adenoviral and
lentiviral vectors for transient and stable expression, respectively.
Expression of human immunoglobulin within adenovirally-trans-
duced HB1.F3 NSCs (HB1.F3.Ad-H2IgG; Fig. 1C) and
HB1.F3.Lenti-H2IgG, a stable cell line generated by lentiviral
transduction of HB1.F3 NSCs (Fig. 1D), was visualized using
immunocytochemistry. These results were confirmed by intracel-
lular flow cytometry (Fig. 1E). Both transient transfection with
Lipofectamine and transduction with adenovirus resulted in a
subpopulation of cells that experessed human IgG, as shown by
the increased fluorescence intensity. In contrast, the stable
HB1.F3.Lenti-H2IgG cell line showed a shift in green fluorescence
intensity for the entire cell population, albeit at lower levels than
with the transient expression methods. This is consistent with a
stable cell line.
To determine whether the NSC-secreted anti-HER2 antibody
binds specifically to the HER2 receptor, HB1.F3-H2IgG cells were
co-cultured overnight with either MCF7 human breast cancer cells
that express low levels of HER2, or MCF7/HER2 cells, an MCF7
line stably transfected to overexpress HER2 [16]. Breast cancer
cells were pre-labeled with CM-DiI to visually distinguish them
from NSCs in co-culture. MCF7/HER2 cells in the vicinity of
transfected NSCs were strongly labeled with human IgG (Fig. 2B).
In contrast, we did not detect any human immunoglobulin bound
to the surface of neighboring MCF7 cells (Fig. 2A). To confirm
specificity, supernatant from transfected or transduced HB1.F3
cells was incubated with MCF7, MCF7/HER2, or BT474, a
human breast cancer cell line that endogenously overexpresses
HER2. Antibody bound to breast cancer cells was detected by flow
cytometry (Fig. 2C), and significant quantities of human IgG were
detected on the surface of both HER2-overexpressing cell lines
following incubation with supernatant from HB1.F3-H2IgG
and HB1.F3.Ad-H2IgG NSCs. Supernatant from stable
HB1.F3.Lenti-H2IgG NSCs also labeled HER2-overexpressing
breast cancer cells, but to a lesser extent. This result is consistent
with the lower expression levels observed by intracellular flow
cytometry of HB1.F3.Lenti-H2IgG cells. Importantly, each
supernatant labeled MCF7 cells between one and two logs less
than either of the HER2-overexpressing breast cancer cell lines.
These findings demonstrate the NSC-secreted antibody is specific
for HER2.
NSC-Secreted IgG Is Functionally Equivalent to
Trastuzumab
To directly compare trastuzumab and NSC-secreted anti-
HER2 antibody (F3-IgG), F3-IgG was purified from the
supernatant of transfected HB1.F3 cells. Trastuzumab and F3-
IgG were analyzed by SDS-PAGE under reducing and non-
Figure 1. Expression of human IgG in NSCs. Fluorescence
micrograph of parental HB1.F3 NSCs (A), HB1.F3.H2IgG (B), HB1.F3.A-
deno-H2IgG NSCs (C), and HB1.F3.Lenti-H2IgG (D). Cells were stained
with anti-human IgG (green) and DAPI nuclear stain (blue). Expression
was confirmed by intracellular flow cytometry of fixed and permeabi-
lized NSCs (E). Fluorescence of fixed and permeabilized parental NSCs
(indicated by gray histogram) was used to set the marker for each
graph.
doi:10.1371/journal.pone.0008314.g001
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molecular mass of 150 kDa under non-reducing conditions and
two major bands indicative of the heavy (50 kDa) and light (25
kDa) chains under reducing conditions (data not shown). This
suggests the two antibodies have a similar molecular composition.
To confirm the specificity of F3-IgG, purified F3-IgG was added
directly to target cells and binding was detected by flow cytometry.
At all concentrations tested, trastuzumab and purified F3-IgG
bound equally well to MCF7/HER2 and BT474, as indicated by
similar mean fluorescence intensities of assayed target cells
(Fig. 3A). A non-specific isotype control antibody (human IgG1)
showed no reactivity. Minimal labeling of MCF7 cells was
observed for both trastuzumab and F3-IgG. This indicates that
F3-IgG binds to HER2 protein specifically and with an affinity
comparable to that of trastuzumab, which suggests that it should
have similar anti-tumor efficacy.
To assess the ability of F3-IgG to inhibit the proliferation of
HER2-overexpressing breast carcinoma cells, we measured the
proliferation of BT474, MCF7/HER2 and MCF7 breast cancer
cell lines in the presence of trastuzumab, F3-IgG, or an isotype-
matched control antibody. F3-IgG significantly inhibited the
proliferation of BT474 cells in a dose-dependent manner,
comparable to the trastuzumab (Fig. 3B). As expected, MCF7
cells were not affected by treatment with either trastuzumab or F3-
IgG. F3-IgG did not inhibit the proliferation of MCF7/HER2
cells, which is consistent with previously published reports for
trastuzumab [16,17].
Antibody-Secreting NSCs Display Tumor Tropism and
Deliver Antibody to Breast Cancer Xenografts
In order for stem cell targeting of antibodies to be clinically
relevant, immunoglobulin-secreting NSCs must retain their
migratory tumor-tropic properties. We tested the migration of
transfected NSCs in vitro using a chemotaxis assay in which cells
must actively migrate through a semi-permeable membrane in
response to a cytokine gradient. Both parental HB1.F3 NSCs and
NSCs expressing intact anti-HER2 immunoglobulin showed
preferential in vitro migration to tumor cell-conditioned media.
Although we observed fewer migrated anti-HER2-expressing
NSCs than untransfected NSCs, both cell types showed a
statistically significant tropism to MCF7/HER2 conditioned
medium relative to BSA control (Fig. 4). This result indicates that
immunoglobulin-expressing HB1.F3 NSCs would likely maintain
the in vivo tumor tropism of the parental NSC line.
We next tested the ability of antibody-expressing NSCs to deliver
anti-HER2 antibodies to tumor foci in vivo using a xenograft nude-
beige mouse model. Intravenously-injected parental and transduced
HB1.F3 NSCs were detected within the tumor mass of each treated
animal by immunohistochemistry. Tumor sections from animals
receiving NSCs showed a patchy distribution of NSCs (CM-DiI
labeled, red) within the tumor. In contrast, tumor sections from mice
receiving trastuzumab injections showed no red stained cells (Fig. 5).
The presence of NSCs within the tumor mass was confirmed by
detection of v-myc DNA using nested PCR. A 293 bp PCR product
was detected in the tumors of every mouse treated with HB1.F3,
HB1.F3.Ad-H2IgG, or HB1.F3.Lenti-H2IgG. In contrast, no PCR
product was detected in tumors from mice treated with trastuzumab
alone. Tumor sections were then stained with FITC-conjugated anti-
human IgG. Tumor sections from trastuzumab-injected animals
showed patches of bright green cobblestone patterns, indicative of
antibody bound to tumor cell membranes. As expected, trastuzumab
distribution was heterogeneous and localized in the vicinity of tumor
vasculature. Tumor sections from mice treated with HB1.F3.Ad-
H2IgG and HB1.F3.Lenti-H2IgG also showed patches of green
cobblestone patterns throughout the tumor mass. Antibody-express-
ing NSC appear yellow, due to the presence of both CM-DiI and
FITC-conjugated anti-human IgG. Parental HB1.F3 NSCs showed
onlybackgroundlevelsofgreenfluorescence andtumorsectionsfrom
mice injected with these NSCs did not exhibit the green cobblestone
pattern associated with membrane-bound antibody.
Of note, quantitative ELISA revealed significant quantities of
human IgG in the blood of trastuzumab-injected mice. In contrast,
Figure 2. NSC-secreted human IgG specifically binds HER2. Transfected NSCs were co-cultured with CM-DiI-labeled (red) MCF7 (A) or MCF7/
HER2 cells (B) and stained with FITC-conjugated anti-human IgG (green) and DAPI (blue). Arrows indicate NSCs expressing human IgG that does not
bind to adjacent MCF7 control cells (A) or areas of NSC-secreted human IgG bound to MCF7/HER2 target cells (B). Bar, 50 mm. Flow cytometric
analysis of BT474, MCF7/HER2, or MCF7 target cells after incubation with supernatant from HB1.F3.H2IgG, HB1.F3.Adeno-H2IgG, or HB1.F3.Lenti-
H2IgG (C), followed by incubation with FITC-conjugated anti-human IgG (blue histograms). Red histograms on each graph show target cells
incubated with supernatant from unmodified HB1.F3 NSCs as a negative control.
doi:10.1371/journal.pone.0008314.g002
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IgG at the tumor site, but no human IgG was detectable in the
blood (data not shown). Taken together, these data indicate that
anti-HER2 IgG-expressing NSCs can deliver antibody selectively
to tumor foci in vivo.
Discussion
Overexpression of HER2 is a marker for poor prognosis in breast
cancerand isoftencorrelatedwithincreasedmetastasis,includingto
the CNS [18,19]. Trastuzumab directly inhibits the proliferation of
HER2-overexpressing breast cancer cells and induces immune-
mediated killing of target cancer cells through antibody-dependent
cellular cytotoxicity [20]. However, trastuzumab is unable to cross
the BBB, and therefore cannot be used to treat CNS metastases.
Importantly, NSCs can target breast cancer metastasis in the brain
[9] and can penetrate deep and hypoxic regions of solid tumors [7].
Therefore, we examined the feasibility of expressing therapeutic
antibodies in tumor-tropic human NSCs, with the ultimate goal of
using such NSCs as a platform for delivery of anti-HER2 antibody
to otherwise inaccessible tumor foci.
NSCs have been successfully engineered to express and deliver a
broad range of recombinant therapeutic proteins to tumor foci [3].
However, antibodies are complex tetrameric molecules, that are
normally expressed only by lymphocytes and a few other
specialized cells. Whether NSCs are capable of expressing and
secreting such complex molecules was previously unknown. Here,
we have demonstrated that NSCs can express and secrete intact
immunoglobulin while retaining their inherent tumor tropism. In
addition, F3-IgG binds to HER2 specifically and inhibits the
proliferation of HER2-overexpressing breast cancer cells.
In our initial experiments, we transiently co-transfected
trastuzumab heavy and light chains with Lipofectamine to achieve
trastuzumab expression in HB1.F3 NSCs. Although this method
was successful in generating high levels of human IgG in HB1.F3
NSCs, expression was limited to 3–4 days and caused unpredict-
able toxicity to the NSCs. We therefore chose to pursue two
alternative viral transduction strategies to prolong antibody
expression. Our laboratory has previously used adenoviral
expression as a means to transiently express therapeutic transgenes
[2,6]. We have found that adenoviral transduction results in high
levels of transgene expression for at least two weeks. We have also
generated a stable anti-HER2 IgG-expressing NSC line
(HB1.F3.Lenti-H2IgG). In this stable line, antibody expression is
prolonged, but at significantly lower levels than observed with
adenovirally-transduced NSCs (HB1.F3.Ad-H2IgG). Both of these
strategies resulted in antibody-expressing NSCs capable of
Figure 3. NSC-secreted anti-HER2 antibody is functionally equivalent to trastuzumab. Flow cytometric analysis (A) of MCF7, MCF7/HER2,
and BT474 cells labeled with F3-IgG, trastuzumab, or a human IgG isotype control antibody. Graphs show mean fluorescence intensity (MFI) of
labeled cells. Inhibition of cell proliferation (B) of MCF7, MCF7/HER2, or BT474 cells treated for 6 days with F3-IgG, trastuzumab, or isotype control
antibody. Graphs show proliferation as a percentage of untreated cells.
doi:10.1371/journal.pone.0008314.g003
Figure 4. In vitro migration of NSCs to breast carcinoma
conditioned media. Migration of parental NSCs and anti-HER2-
transfected HB1.F3 NSCs to breast tumor-conditioned media in an in
vitro chemotaxis assay. In this assay, bovine serum albumin (BSA) was
used as a negative control for chemotaxis. Both parental and
transfected NSC lines preferentially migrated to MCF7/HER2 compared
to negative control (2% BSA) (p,0.01).
doi:10.1371/journal.pone.0008314.g004
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detect anti-HER2 antibody at the tumor site but not in the blood
of NSC-treated mice suggests that this approach could have robust
localized anti-tumor effect, while minimizing the systemic toxicity
associated with traditional trastuzumab therapy.
The use of NSCs to target antibodies specifically to tumor foci
has broad implications for the field of antibody therapy in cancer
and other diseases. In addition to improving distribution of
antibodies to the CNS and within malignant solid tumors, this
strategy could expand the number of targets to which antibodies
can be directed. Currently, molecular targets for cancer therapy
must either be exclusively expressed by tumor cells or expressed at
significantly higher levels in tumors than in normal tissues.
Because the tumor specificity of NSC-mediated immunotherapy is
endowed by the NSCs, antigens on tumor cells can likely be safely
targeted, regardless of whether they are present in healthy tissues.
We conclude that tumor-tropic human NSCs can be genetically
modified to secrete intact therapeutic antibodies. The data
presented here provide the first fundamental step in the
development of a stem cell-based cancer immunotherapy. Such
a therapeutic platform has significant clinical implications for
improving the treatment of metastatic breast carcinoma and other
malignant solid tumors.
Materials and Methods
Vector Construction and Purification
DNA encoding the trastuzumab scFv molecule (hu4D5v8) was
generated as described previously [21]. The genes encoding the
variable domains were individually inserted on to the human IgG1
heavy and light chains by splice-overlap PCR using the anti-CEA
hT84.66-M5A antibody as a template and cloned into glutamine
synthetase vectors (Lonza Biologics, Slough, UK) as previously
described [21]. To create viral expression vectors, a bicistronic
construct was created. Briefly, trastuzumab heavy and light chain
sequences were amplified with PCR and a truncated FMDV 2A
peptide sequence was inserted between them by splice overlap
extension. This expression construct was inserted into the pENTR
vector of Invitrogen’s Gateway system using the D-TOPO cloning
kit. Entry vector constructs were recombined into adenoviral (pAd,
Invitrogen) or lentiviral (pCSC-Zeo with Gateway recombination
sites cloned into the multiple cloning site) destination vectors
according to manufacturer’s instructions. Adenovirus was produced
by transfecting adenoviral expression vector into E1-complemented
cell line 293A and performing successive rounds of amplification
untilhightiterwasachieved.ViruswasthenpurifiedusingViraBind
Adenovirus Purification Kit (Cell Biolabs). Lentivirus was produced
by cotransfecting replication incompetent lentiviral vector with
psPAX2 (Addgene, 12260) and pLP/VSV-G (Invitrogen). Virus
was purified from crude viral supernatant using LentiX Viral
concentrator (Clontech) according to manufacturer’s instructions.
Cell Culture
HB1.F3, MCF7, MCF7/HER2, 293A and 293FT cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 100 units penicillin,
100 mg/mL streptomycin, and 2 mML-glutamine. BT474 cells were
cultured in RPMI 1640 supplemented with 10% FBS, 100 units
penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine and
500 mg/mL insulin. All cells were cultured at 37uCw i t h6 %C O 2.
Transfection and Transduction of HB1.F3 NSCs
Plasmids encoding the trastuzumab heavy and light chains,
pEE6-HER2-Heavy and pEE12-HER2-Light, were co-transfected
in equal concentrations using Lipofectamine LTX (Invitrogen)
Figure 5. NSCs target breast carcinoma and can deliver anti-HER2 antibody in vivo. Confocal fluorescence micrographs of tumor sections
from MCF7/HER2 xenografts. First three panels in the upper row show the presence of CM-DiI-labeled red NSCs (HB1.F3, HB1.F3.Ad-H2IgG,
HB1.F3.Lenti-H2IgG, respectively) in tumors 4 days after intravenous injection. The fourth panel of the upper row shows tumor with no red NSCs in
mice treated with trastuzumab alone (sporadic small red dots not associated with cells are visible as autofluorescence background). Middle row
shows tumor sections stained with FITC-conjugated anti-human IgG (green). Bar, 50 mm. Insets are 26magnification (Bar, 20 mm). Bottom row shows
confirmation of the presence or absence of HB1.F3 NSCs within tumors by PCR detection of a DNA amplicon (293 bp) of the v-myc transgene, a
unique identifier of the HB1.F3 cell line.
doi:10.1371/journal.pone.0008314.g005
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diameter) were seeded with HB1.F3 NSCs (3610
6) and transfected
with pooled heavy and light chain DNA (6 mg). Stable trastuzu-
mab-expressing NSCs (HB1.F3.Lenti-H2IgG) were generated by
incubating HB1.F3 cells with purified lentivirus (MOI 100) for 4 h
in the presence of 8 mg/mL polybrene. After 24 h, trastuzumab-
expressing NSC were selected using increasing concentrations of
Zeocin (InvivoGen), beginning at 100 mg/mL. For adenoviral
transduction, HB1.F3 cells were incubated with purified adeno-
virus (1:1000 dilution in DMEM) for 4 h and then cultured
overnight in DMEM.
Mouse Tumor Xenograft Model
Female 7-week old nude-beige-xid mice (NCI) were injected
with MCF7/HER2 cells (5610
6) in the right mammary fat pad.
Tumors were allowed to grow until palpable (3 weeks), then mice
were injected intravenously with trastuzumab (4 mg/kg) or
unmodified NSCs (2610
6), adenovirally-transduced NSCs or
HB1.F3/H2IgG (3 mice per group). One additional mouse per
group received an intratumoral injection as a control. Four days
later, mice were humanely euthanized and tumors were harvested
and fixed for 48 h in 4% PFA. Blood was collected by cardiac
puncture immediately after euthanasia. All procedures were
approved by City of Hope IACUC.
PCR Detection of v-myc
Genomic DNA from tumor sections was purified using DNeasy
Blood and Tissue kit (Qiagen). Nested PCR was performed as
described previously [2]. The v-myc amplicon was detected as a
band of 293 bp. Genomic DNA from HB1.F3.H2IgG cells was
used as a positive control.
Quantitative ELISA
Mouse serum was diluted 100 or 1000-fold in PBS and tested by
quantitative ELISA using the human IgG ELISA Kit (Bethyl
Laboratories) according to manufacturer’s instructions.
Immunocytochemistry and Immunohistochemistry
Parental or transfected/transduced NSCs were seeded into 4-
well chamber slides and allowed to adhere overnight. For co-
culture experiments, CM-DiI-labeled breast cancer cells were
seeded one day prior to the addition of NSCs. Adherent cells were
washed once (PBS supplemented with 100 mg/L calcium chloride
and 100 mg/L magnesium chloride), fixed (4% paraformalde-
hyde, 10 min), then permeabilized (0.3% Triton X-100 in PBS,
30 min). For tissue sections, PFA-fixed tumors were impregnated
with 30% sucrose then cut into 10 mm sections using a cryostat.
Sections were blocked and stained overnight with FITC-
conjugated donkey anti-human IgG (H+L) (Jackson ImmunoR-
esearch). Slides were washed, counterstained with 49,6-diamidino-
2-phenylindole (DAPI), mounted in fluorescent mounting media
(DAKO), and imaged using a Nikon Eclipse TE2000-U
microscope equipped with a SPOT RT Slider digital camera or
confocal imaging using a Zeiss LSM 510 confocal microscope
(Carl Zeiss Microimaging).
Purification of Secreted Antibody
Immunoglobulin-containing HB1.F3.H2IgG NSC culture super-
natant was subjected to purification by protein A affinity chroma-
tography. TheNSC-expressed anti-HER2antibody and trastuzumab
were analyzed by SDS-PAGE as previously described [21].
Flow Cytometry
The specificity of purified NSC-secreted antibody (F3-IgG) was
compared to trastuzumab by measuring the binding to HER2 over-
expressing target cells. Bound immunoglobulin on target cells was
labeled with FITC-conjugated donkey anti-human IgG (H+L)
(Jackson ImmunoResearch) and detected using a Guava EasyCyte
flow cytometer. For intracellular flow cytometry, cells were fixed in
4% PFA for 20 min, then washed and resuspended in permeabiliza-
tion buffer (PBS with 3% FBS and 0.1% Saponin) prior to staining.
Cell Proliferation Assay
Breast carcinoma cells (5610
3 cells/well) were seeded into a 96-
well plate and treated with trastuzumab, isotype-matched control
IgG, or F3-IgG at concentrations ranging from 0.01 to 10 mg/mL.
As a negative control, medium alone (100 mL) was added. Plates
wereincubated (37uC) for 5 or 6 days. To quantify cell proliferation,
WST-1 reagent (Roche) was used according to manufacturer’s
instructions. Background absorbance of WST-1 with media only
was subtracted and all concentrations were expressed as a
percentage of control. All experiments were performed in triplicate.
In Vitro Chemotaxis Assay
Cell migration assay was performed as described previously
[22]. Briefly, NSCs (1610
5 in 400 mL culture media) were seeded
into the upper chamber of a 24-well Boyden chamber with an
8 mm pore-size membrane, and tumor cell-conditioned medium
(600 mL) was added to the bottom chamber. After 4 h, the number
of migrated cells was quantified using a Guava EasyCyte flow
cytometer. NSCs transfected with anti-HER2 antibody were used
24 h after transfection, the time-point that correlated with peak
antibody expression. All experiments were performed in triplicate.
Student’s t-test was used for statistical analysis. p,0.05 was
considered significant.
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